Acesso livre
Acesso livre

Terapia Intensiva

Outro estudo randomizado mostrou que o plasma convalescente não beneficia pacientes internados com Covid-19.

1 Dez, 2021 | 15:36h

Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial – JAMA Network Open

Conteúdos relacionados:

M-A: Convalescent plasma does not reduce mortality in COVID-19.

RCT: Another study shows convalescent plasma does not improve outcomes in critically ill patients with Covid-19.

RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19.

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.

M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

 

Comentário no Twitter

 

M-A | Eficácia das estratégias de manejo respiratório invasivo e não invasivo em adultos com insuficiência respiratória hipoxêmica aguda.

1 Dez, 2021 | 15:27h

Efficacy of non-invasive and invasive respiratory management strategies in adult patients with acute hypoxaemic respiratory failure: a systematic review and network meta-analysis – Critical Care

Estudo randomizado preliminar mostra que a prostaciclina pode melhorar os desfechos em pacientes sob ventilação mecânica com COVID-19 e endoteliopatia grave.

30 Nov, 2021 | 12:25h

Prostacyclin in Mechanically Ventilated Patients with COVID-19 and Severe Endotheliopathy: A Multicenter, Randomized, Clinical Trial – American Journal of Respiratory and Critical Care Medicine

Comunicado de imprensa: Well-known drug could help the most severely affected COVID-19 patients in intensive-care departments – by University of Copenhagen

 

Comentário do autor no Twitter (fio – clique para saber mais)

 

Diretrizes ESCMID para COVID-19 | Tratamento medicamentoso e abordagem clínica.

30 Nov, 2021 | 12:23h

ESCMID COVID-19 Living guidelines: drug treatment and clinical management – Clinical Microbiology and Infection

Monitoramento eletrocardiográfico em posição prona na síndrome da angústia respiratória aguda por Covid-19.

30 Nov, 2021 | 12:21h

Electrocardiogram monitoring in the prone position in coronavirus disease 2019 acute respiratory distress syndrome – European Journal of Cardiovascular Nursing

 

Comentário no Twitter

 

Estudo randomizado | Cateter percutâneo 14-Fr de pequeno calibre (pigtail) foi tão efetivo quanto cateteres 28 a 32-Fr em sua capacidade de drenar hemotórax traumático, sem diferença nas complicações.

30 Nov, 2021 | 12:15h

The small (14 Fr) percutaneous catheter (P-CAT) versus large (28–32 Fr) open chest tube for traumatic hemothorax: A multicenter randomized clinical trial – Trauma and Acute Care Surgery (link para o resumo – $ para o texto completo)

Revisão sistemática | Anticoagulantes para AVC isquêmico agudo.

30 Nov, 2021 | 12:09h

Resumo: Early treatment with blood-thinning drugs for people who have had a stroke – Cochrane Library

Estudo original: Anticoagulants for acute ischaemic stroke – Cochrane Library

Podcast | Alcalose metabólica e hipocalemia.

30 Nov, 2021 | 12:06h

#308 Metabolic Alkalosis and Hypokalemia: Kidney Boy Returns! – The Curbsiders

[Comunicado de imprensa – Ainda não publicado] Dados atualizados sobre a nova pílula da Merck contra Covid (molnupiravir) mostram eficácia reduzida (30%) em evitar internação e morte, em comparação aos resultados iniciais (50%). O risco absoluto em reduzir internação e morte caiu de 7% para 3%.

29 Nov, 2021 | 11:01h

Comunicado de imprensa: Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19

Comentário: New data, analyses take some of the shine off Merck’s Covid pill – STAT

Conteúdos relacionados:

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Comentários no Twitter

 

Revisão | Prevenção e tratamento de trombose em pacientes internados com pneumonia por COVID-19.

26 Nov, 2021 | 12:04h

Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia – The Lancet Respiratory Medicine

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.